Close Menu

Most people agree that biotech is the future, and that Big Pharma companies should take an interest if they want to continue to thrive. Sanofi-Aventis has already made inroads into biotech with a $20 billion takeover of Genzyme. And while the deal is a "bet on the future," Genzyme's short-term benefits for Sanofi may be more important, says Jonathan Rockoff on the Wall Street Journal's Health Blog.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.